Findings of ¹⁸ F-PI-2620 tau PET imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma P-tau181 levels in a Japanese sample.

ABSTRACT:

Background

Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD, abnormal tau accumulates within neurons of the brain, facilitated by extracellular β-amyloid deposition, leading to neurodegeneration, and eventually, cognitive impairment. As this process is thought to be irreversible, early identification of abnormal tau in the brain is crucial for the development of new therapeutic interventions.

Aims

¹⁸ F-PI-2620 is one of the second-generation tau PET tracers with presumably less off-target binding than its predecessors. Although a few clinical studies have recently reported the use of ¹⁸ F-PI-2620 tau PET in patients with AD, its applicability to AD is yet to be thoroughly examined.

Methods

In the present pilot study,

SUBMITTER: Bun S 

PROVIDER: S-EPMC9773651 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature